title: Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.
abstract: The aberrant fibrotic and repair responses in the lung are major hallmarks of idiopathic pulmonary fibrosis (IPF). Numerous antifibrotic strategies have been used in the clinic with limited success, raising the possibility that an effective therapeutic strategy in this disease must inhibit fibrosis and promote appropriate lung repair mechanisms. IL-13 represents an attractive target in IPF, but its disease association and mechanism of action remains unknown. In the present study, an overexpression of IL-13 and IL-13 pathway markers was associated with IPF, particularly a rapidly progressive form of this disease. Targeting IL-13 in a humanized experimental model of pulmonary fibrosis using tralokinumab (CAT354) was found to therapeutically block aberrant lung remodeling in this model. However, targeting IL-13 was also found to promote lung repair and to restore epithelial integrity. Thus, targeting IL-13 inhibits fibrotic processes and enhances repair processes in the lung.
authors: 1 MedImmune Ltd, Cambridge, United Kingdom.
authors: Lynne A
authors: LA
authors: Murray
authors: Huilan
authors: H
authors: Zhang
authors: Sameer R
authors: SR
authors: Oak
authors: Ana Lucia
authors: AL
authors: Coelho
authors: Athula
authors: A
authors: Herath
authors: Kevin R
authors: KR
authors: Flaherty
authors: Joyce
authors: J
authors: Lee
authors: Matt
authors: M
authors: Bell
authors: Darryl A
authors: DA
authors: Knight
authors: Fernando J
authors: FJ
authors: Martinez
authors: Matthew A
authors: MA
authors: Sleeman
authors: Erica L
authors: EL
authors: Herzog
authors: Cory M
authors: CM
authors: Hogaboam
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D004847:Epithelial Cells / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy* / Q000378:metabolism; D018793:Interleukin-13 / Q000378:metabolism*; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D016513:Mice, SCID; D058990:Molecular Targeted Therapy; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D018793:Interleukin-13; C574065:tralokinumab